Physician

Internal Medicine

Richard practices Internal Medicine. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He has 1 awards "CMS Meaningful Use Stage 1 Certification". Richard has written publications. He has 98 publications published with PubMed. The lastest publication is: 'The Alton Ochsner Medical Foundation.'

Publications

---

• Could Intracrine Biology Play a Role in the Pathogenesis of Transmissable Spongiform Encephalopathies, Alzheimer's Disease and Other Neurodegenerative Diseases?
• Invited Review: Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model.
• Predictors of Decline in Medication Adherence: Results From the Cohort Study of Medication Adherence Among Older Adults.
• Cell-Penetrating Peptides Corresponding to the Angiotensin II Type 1 Receptor Reduce Receptor Accumulation and Cell Surface Expression and Signaling.
• Noncanonical intracrine action.
• Expression of a Naturally-Occuring Angiotensin AT1 Receptor Cleavage Fragment Elicits Caspase-Activation and Apoptosis.
• The lysosomal action of intracrine angiotensin II.
• Ochsner research update.
• A regulatory approach to health care reform.
• Quality of life in hypertensive clinic patients following hurricane katrina.
• The mitochondrial component of intracrine action.
• Senescence, apoptosis, and stem cell biology: the rationale for an expanded view of intracrine action.
• New insights into target organ involvement in hypertension.
• Research update.
• Obesity-related hypertension.
• New medication adherence scale versus pharmacy fill rates in seniors with hypertension.
• Medication adherence in older clinic patients with hypertension after Hurricane Katrina: implications for clinical practice and disaster management.
• The physiological basis of intracrine stem cell regulation.
• The trafficking protein GABARAP binds to and enhances plasma membrane expression and function of the angiotensin II type 1 receptor.
• The basis of an intracrine pharmacology.
• Cleavage of the angiotensin II type 1 receptor and nuclear accumulation of the cytoplasmic carboxy-terminal fragment.
• Do we need yet another blocker of the renin-angiotensin system?
• Inhibition of Erythroleukemia Cell Growth by Triplex-forming RNAs.
• An intracrine view of angiogenesis.
• Research night 2005.
• The role of research in the modern medical center: the ochsner clinic foundation perspective.
• Reliability of a medication adherence measure in an outpatient setting.
• Tissue renin angiotensin systems.
• Intracellular renin and the nature of intracrine enzymes.
• Application of the combined quality improvement ratio in the evaluation of a quality improvement activity in a managed care organization.
• Cardiac angiotensin II: an intracrine hormone?
• The intracrine hypothesis and intracellular peptide hormone action.
• Implications of intracrine hormone action for physiology and medicine.
• Accuracy of telemedicine in detecting uncontrolled hypertension and its impact on patient management.
• The origins of intracrine hormone action.
• Annual Progress Report and Our Thanks to Referees.
• C-terminal processing of GABARAP is not required for trafficking of the angiotensin II type 1A receptor.
• Renin excess after renin inhibition: malefactor or innocent bystander?
• Mechanisms of disease: Intracrine physiology in the cardiovascular system.
• Potential therapeutic implications of intracrine angiogenesis.
• Toward a theory of intracrine hormone action.
• Intracellular angiotensin II increases the long isoform of PDGF mRNA in rat hepatoma cells.
• The intracrine hypothesis: an update.
• Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease.
• Nuclear accumulation of the AT1 receptor in a rat vascular smooth muscle cell line: effects upon signal transduction and cellular proliferation.
• The inhibition of tumor growth by triplex-forming oligonucleotides.
• A proposal regarding the biology of memory: participation of intracrine peptide networks.
• Intracellular angiotensin II fusion protein alters AT1 receptor fusion protein distribution and activates CREB.
• Intracellular renin-angiotensin system: the tip of the intracrine physiology iceberg.
• Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care.
• In vitro evidence for an intracellular site of angiotensin action.
• Health status assessment in a hypertension section of an internal medicine clinic.
• Combined quality improvement ratio: a method for a more robust evaluation of changes in screening rates.
• Patient and physician satisfaction in a clinical study of telemedicine in a hypertensive patient population.
• Transgenic mice expressing an intracellular fluorescent fusion of angiotensin II demonstrate renal thrombotic microangiopathy and elevated blood pressure.
• The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells.
• The nature of intracrine peptide hormone action.
• The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues.
• Angiotensin and the regulation of cellular growth. Pathophysiologic implications for cardiovascular and noncardiovascular tissues.
• Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?
• Effects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies.
• Predicting work status for patients in an occupational medicine setting who report back pain.
• Comparing comorbid-illness indices assessing outcome variation: the case of prostatectomy.
• How to use continuous quality improvement theory and statistical quality control tools in a multispecialty clinic.
• Growth factors and cardiovascular structure. Implications for calcium antagonist therapy.
• Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate.
• Cellular mechanisms of growth in cardiovascular tissue.
• Renin-angiotensin system: genes to bedside.
• ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin.
• Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells.
• A method to report utilization for quality initiatives in medical facilities.
• Introduction to the focussed section on molecular and cellular biology in hypertension.
• The application of antisense technology to medicine.
• The Alton Ochsner Medical Foundation.
• The effect of education on patients'' willingness to participate in a telemedicine study.
• The application of molecular genetic techniques to the study of hypertensive diseases.
• Emerging issues in the cellular biology of the cardiovascular system.
• Adenovirus-mediated in vivo gene transfer in a rabbit model of allograft vasculopathy.
• Testing efficacy with detection controlled estimation: an application to telemedicine.
• Nobel laureates honored by the council for high blood pressure research.
• Controversies in the genetic analysis of hypertensive diseases.
• Development of innovative therapies in the large multispecialty clinic setting.
• Myocardial hypertrophy, angiotensin, and ACE inhibitors.
• Cellular biology of the renin-angiotensin systems.
• The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects.
• Functional intracellular renin-angiotensin systems may exist in multiple tissues.
• The renin-angiotensin systems.
• The role of the renin--angiotensin--aldosterone system in cardiovascular homeostasis in normal man.
• The myocardial intracellular renin-angiotensin system.
• The clinical implication of tissue renin angiotensin systems.
• Characterization of the renin-aldosterone system in decompensated cirrhosis.
• Specific nuclear binding of angiotensin II by rat liver and spleen nuclei.
• The characterization of low renin hypertension by plasma renin activity and plasma aldosterone concentration.
• On the biological actions of intracellular angiotensin.
• The Norman Nigro Lectureship. New paradigms of oncogenesis and their implications for surgery in the twenty-first century.
• New approaches to the study of the cellular biology of the cardiovascular system.
• Studies on two novel angiotensin II actions.

Schools

---

• Harvard Medical School

• Massachusetts General Hospital

• Harvard Medical SchoolMassachusetts General Hospital

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• Massachusetts General Hospital
• Harvard Medical School

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Le K. Nguyen, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas E. Nolan, MD
	Dr. Alina D. Fotino, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert Occhipinti, MD This Doctor is OpenDoctor Recommended.
	Dr. Jonathan M. Gugel, MD This Doctor is OpenDoctor Recommended.
	Dr. Vijayendra R. Jaligam, MD This Doctor is OpenDoctor Recommended.
	Dr. Dana L. Ellis, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog